including 4,900 in France.
3 major R&D areas
oncology, neurology/immune-inflammatory and cardio-metabolism
100 million patients
treated daily with Servier medicinal products and generics.
in which the Group’s medicines are distributed.
15 International Centres for Therapeutic Research
and 4 research institutes.
16 chemical & pharmaceutical production sites
4.7 billion euros in turnover
comprising 3.2 billion euros for Servier and 1.4 billion euros for generics.
23 % of turnover from Servier drugs is invested in R&D
2nd largest pharmaceutical Group in France
31st largest pharmaceutical Group worldwide
A leader in cardiology
no. 6 Group in the world (Source: IQVIA Q3 2019).
in clinical development, including 16 new molecular entities
Participation reached 36% of the trade balance surplus in France
In pharmaceuticals and fine chemicals (brand-name medicines), amounting to 1.6 billion euros.